Gravanis, I., Tzogani, K., van Hennik, P., de Graeff, P., Schmitt, P., Mueller‐Berghaus, J., Salmonson, T., Gisselbrecht, C., Laane, E., Bergmann, L., & Pignatti, F. (2016). the European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Oncologist, 21, 102–109. http://access.bl.uk/ark:/81055/vdc_100054334469.0x000025